Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18FDG and 64Cu-DOTA-Trastuzumab ...
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis Machine Learning to Predict ...
Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection FGFR2b protein overexpression at any % and ≥10%, 2+/3+ TC positivity was 37.8% (1,428 ...
Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program: A Collaboration Between Hematology Oncology Pharmacist Association and ASCO Quality Training ...
We included 11 RCTs with 2,177 patients in this review. Patients' age ranged from 60 to 95, and the median number of patients per study was 147 (range, 44-690). Most studies included patients with ...
Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback